Discussion
Stoke Therapeutics says it’s aligned with the U.S. Food and Drug Administration (FDA) on key aspects of a planned application seeking approval of zorevunersen for Dravet syndrome — including how to analyze data from an ongoing Phase 3 clinical trial testing the potential anti-seizure med. According to…